PO Box 11239
Blacksburg, VA 24062
United States
540-218-2232
https://landosbiopharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 19
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Gregory Oakes | President, CEO & Director | 1.05M | N/A | 1969 |
Dr. Fabio Cataldi M.D. | Executive VP & Chief Medical Officer | 732.29k | N/A | 1968 |
Ms. Jennifer Creel | Interim Chief Financial Officer | N/A | N/A | 1971 |
Ms. Rebecca Mosig Ph.D. | Vice President of Corporate Development | N/A | N/A | N/A |
Dr. Josep Bassaganya-Riera DVM, Ph.D. | Advisor | 1.79M | N/A | 1975 |
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Landos Biopharma, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 9.